CITATION REPORT List of articles citing



DOI: 10.1007/s100670050033 Clinical Rheumatology, 2000, 19, 142-6.

Source: https://exaly.com/paper-pdf/31633619/citation-report.pdf

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
25	Gout: diagnosis, pathogenesis, and clinical manifestations. <i>Current Opinion in Rheumatology</i> , 2001 , 13, 234-9	5.3	56
24	Gout and hyperuricemia. Current Opinion in Rheumatology, 2002, 14, 281-6	5.3	137
23	A literature review of the epidemiology and treatment of acute gout. <i>Clinical Therapeutics</i> , 2003 , 25, 1593-617	3.5	187
22	Clinical manifestations and treatment of gout. Primary Care Update for Ob/Gyns, 2003, 10, 19-23		9
21	Purine metabolism and hyperuricemic states. The point of view of the rheumatologistY <i>Contributions To Nephrology</i> , 2005 , 147, 1-21	1.6	5
20	Crystal-associated arthritis in the elderly. Clinics in Geriatric Medicine, 2005, 21, 491-511, v-vi	3.8	6
19	Crystal-associated arthritis in the elderly. Rheumatic Disease Clinics of North America, 2007, 33, 33-55	2.4	21
18	Management of gout in older adults: barriers to optimal control. <i>Drugs and Aging</i> , 2007 , 24, 21-36	4.7	23
17	Gout attack with unusual ocular complications. Rheumatology International, 2009, 29, 557-9	3.6	7
16	Female gout: age and duration of the disease determine clinical presentation. <i>Journal of Clinical Rheumatology</i> , 2012 , 18, 242-5	1.1	3
15	3. Klinik und Diagnostik der Gicht.		
14	Clinical Features and Treatment of Gout. 2017 , 1620-1644.e4		2
13	Chronic tophaceous gout as the first manifestation of gout in two cases and a review of the literature. <i>Seminars in Arthritis and Rheumatism</i> , 2018 , 47, 843-848	5.3	5
12	SAT0404 PRETREATMENT AND CO-ADMINISTRATION WITH METHOTREXATE IMPROVED DURABILITY OF PEGLOTICASE RESPONSE: A PROSPECTIVE, OBSERVATIONAL, PROOF-OF-CONCEPT, CASE SERIES. 2019 ,		1
11	SAT0402 SEL-212 PHASE 2 CLINICAL STUDY IN SYMPTOMATIC GOUT PATIENTS: IMMTOR TOLEROGENIC NANOPARTICLES COMBINED WITH PEGADRICASE MITIGATES IMMUNOGENICITY AND ENABLES SUSTAINED REDUCTION OF SERUM URIC ACID LEVELS, LOW RATE OF GOUT FLARES		1
10	SAT0403 SEX DIFFERENCES ARE PRESENT IN CLINICAL CHARACTERISTICS, BUT NOT IN RESPONSE TO DIFFERENT URATE LOWERING THERAPIES IN PATIENTS WITH GOUT. 2019 ,		
9	SAT0401 USE OF AND RESPONSE TO METHOTREXATE IN EARLY PSORIATIC ARTHRITIS: RESULTS FROM THE REAL WORLD COHORT, DEPAR STUDY. 2019 ,		1

CITATION REPORT

8	Long-term opioid use among patients with chronic gout: a cross-sectional study of a sample cohort in South Korea. <i>Clinical Rheumatology</i> , 2020 , 39, 3033-3039	3.9	1
7	Sex differences in response to allopurinol and benzbromarone in gout: a retrospective cohort study. <i>Rheumatology Advances in Practice</i> , 2021 , 5, rkab002	1.1	2
6	Gout and Hyperuricemia. 2009 , 1481-1506		5
5	Clinical Features and Treatment of Gout. 2013 , 1554-1575.e5		2
4	The Epidemiology of Gout and Calcium Pyrophosphate Dihydrate Deposition Disease. 2006, 7-35		
3	Clinical Aspects of Gout and Associated Disease States. 2013 , 91-185		
2	Clinical Syndromology of Gouty Arthritis. 2017 , 215-221		
1	Gender characteristics of gout and differences in response to taking xanthioxidase inhibitors. Meditsinskiy Sovet, 2021 , 164-169	0.4	